USR Barcelona

RESPONSABLE
fundanet_file_Investigador4053-2
Daniel Martínez Laguna
dmartinezl.bcn.ics@gencat.cat
avatar_grups_recerca.png

Publications

Value contribution of Etranacogene dezaparvovec for the treatment of severe and moderately severe haemophilia B in Spain through multicriteria decision analysis (MCDA)

D. DIEGO, V. JIMÉNEZ-YUSTE, R. VAZQUEZ, O. HIDALGO, J. POVEDA, J. GIMÉNEZ, J. TRILLO, J. VALLÈS, R. PÉREZ-SANTAMARINA and X. BADIA
HAEMOPHILIA. 2024 Apr 1;

Diagnosing probable urinary tract infections in nursing home residents without indwelling catheters: a narrative review.

Llor C, Moragas A, Ruppe G, Lykkegaard J, Hansen MP, Antsupova VS, Jensen JN, Theut AM, Petek D, Sodja N, Kowalczyk A and Bjerrum L
CLINICAL MICROBIOLOGY AND INFECTION. 2024 Dec 1; . doi:10.1016/j.cmi.2024.08.020; PMID:39209268

Resistant Hypertension and Mortality: An Observational Cohort Study.

de la Sierra A, Ruilope LM, Staplin N, Gorostidi M, Vinyoles E, Segura J, Armario P, Oliveras A and Williams B
HYPERTENSION. 2024 Nov 1; . doi:10.1161/HYPERTENSIONAHA.124.23276; PMID:39247961

Health administration key role in curbing antimicrobial resistance.

Llor C
MEDICINA CLINICA. 2024 Oct 18; . doi:10.1016/j.medcli.2024.04.010; PMID:38926036

Value contribution of etranacogene dezaparvovec gene therapy in moderately severe and severe haemophilia B through multi-criteria decision analysis

D. GARCÍA-DIEGO, X. BADIA, O. BENÍTEZ-HIDALGO, V. JIMÉNEZ, J. JUÁREZ, R. NÚÑEZ, J. POVEDA, J. TRILLO and J. VALLÉS
HAEMOPHILIA. 2024 Sep 28; . doi:10.1111/hae.15096; PMID:39340327

Board of Trustees

Collaborators

Accreditations